Developer docs
API playgroundTry for free, no card

Search company profiles

Vivtex

Full company profile

uuid0009dly

Namestring
Vivtex
Legal namestring
Vivtex Corporation
Websiteurl
vivtex.com
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral biologics delivery, GI screening platform, drug formulation technology, robotic organ interfacing, oral peptide therapeutics
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Biotechnology Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing Revenue
TypeLicensing Royalties
Description

Vivtex licenses its oral drug-delivery technologies to pharmaceutical partners. Revenue includes upfront payments, research funding, milestone payments, and tiered royalties on future product sales.

finance.yahoo.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Vivtex develops and licenses an integrated oral biologics delivery platform comprising the GI-ORIS robotic organ interfacing screening system and an AI-driven gastrointestinal formulation platform. The technology enables high-throughput identification of chemical excipients and formulation strategies that allow injectable biologics, particularly peptides, to be delivered orally. Vivtex licenses this proprietary oral drug-delivery technology to pharmaceutical partners such as Novo Nordisk for development of oral therapeutics in metabolic diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Technology enables oral bioavailability of injectable biologics, enabling convenient pill/tablet dosing for patients requiring frequent long-term treatment
Product overview1 text field

Vivtex is a biotechnology company offering an integrated oral biologics delivery platform comprising the GI-ORIS robotic screening system and an AI-driven gastrointestinal formulation platform. The core technology enables high-throughput identification of chemical excipients and formulation strategies that allow injectable biologics (particularly peptides) to be delivered orally. Vivtex operates as a platform-and-pipeline company, advancing select oral therapeutic candidates through partnerships with pharmaceutical companies while licensing its delivery technologies. The company focuses on disease areas where oral dosing improves patient quality of life and treatment outcomes, particularly in metabolic disorders requiring frequent long-term dosing.

Product and service3 records
1GI-ORIS Platform
CategoryTechnology Platform
Description

A robotic organ interfacing technology that enables high-throughput automated screening of the gastrointestinal tract at the organ level, allowing systematic identification of chemicals and formulation combinations that enable drugs to overcome GI absorption barriers. Designed for pharmaceutical and biotech partners.

2Gastrointestinal Screening and Formulation Platform
CategoryAI Formulation Platform
Description

An AI-driven platform that leverages experimental data from GI-ORIS screening to predict drug-GI interactions and engineer oral formulations for biologics traditionally limited to injection administration. Licensed to pharmaceutical partners for their biologic drug candidates.

3Oral Peptide Therapeutics Pipeline
CategoryTherapeutic Pipeline
Description

Vivtex's active pipeline of oral peptide therapeutics targeting metabolic diseases (obesity, diabetes) and other conditions traditionally requiring injectable medications, developed in partnership with pharmaceutical companies.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Novo Nordisk
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-25
Description

Novo Nordisk partnered with Vivtex in a deal worth up to $2.1 billion to develop next-generation oral biologic medicines for obesity, diabetes, and associated comorbidities. Vivtex licenses its proprietary gastrointestinal screening and formulation platform to enable oral delivery of biologics typically limited to injection. Novo Nordisk leads global development, regulatory activities, manufacturing, and commercialization of resulting products. Vivtex receives upfront payments, research funding, milestone payments, and tiered royalties on future product sales. The collaboration combines Vivtex's oral drug-delivery technologies with Novo Nordisk's peptide and protein therapeutics expertise.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
1Rani Therapeutics
TypeDirect peer
Description

Develops an oral (pill-based) delivery platform for biologics such as peptides, proteins, and antibodies using a robotic auto-injector capsule. Directly competes with Vivtex in the oral biologic delivery space, targeting chronic disease biologics currently requiring injection.

2Entera Bio
TypeDirect peer
Description

Develops oral peptide and protein delivery formulations (e.g., oral PTH, oral GLP-1 analogs) using permeability-enhancing excipients. Competes head-to-head with Vivtex on oral bioavailability of injectable peptides, though with a more formulation-led approach rather than robotic screening.

3Oramed Pharmaceuticals
TypeDirect peer
Description

Pioneer in oral protein delivery (notably oral insulin via POD technology), targeting large injectable biologics for oral reformulation. Most comparable to Vivtex's mission of turning injectable biologics (peptides, hormones) into oral dosage forms.

4Eli Lilly
TypeBroad incumbent
Description

Global pharma leader developing oral GLP-1 candidates (notably orforglipron) and broader oral peptide programs. A potential acquirer/partner for Vivtex and a comp for the value of validated oral obesity therapeutics to large pharma.

5Novo Nordisk
TypeBroad incumbent
Description

Vivtex's flagship partner and the global leader in peptide therapeutics (GLP-1 franchise including Ozempic/Wegovy). Operates its own oral semaglutide and is internalizing oral delivery capability through the Vivtex deal; an essential reference customer and peer for oral biologics.

6Boehringer Ingelheim
TypeBroad incumbent
Description

Large pharma with active oral peptide and biologic programs and partnerships focused on improving bioavailability of injectable biologics. Relevant as both a potential licensee/customer and a benchmark for how major pharma pursues oral peptide delivery.

7BioNxt Solutions
TypeEmerging player
Description

Emerging player developing oral dissolvable thin-film and sublingual delivery of peptides and small molecules. Comparable as a niche company focused on alternative routes of administration versus injectable pharmaceuticals.

8Lindy Biosciences
TypeEmerging player
Description

Develops formulations for oral and high-concentration biologic delivery, including peptide therapeutics. Comparable niche player focused on novel formulations that enable non-injectable administration of biologics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vivtex

Biotechnology Platformvivtex.com

Vivtex firmographics

Firmographics
Name
Vivtex
Legal name
Vivtex Corporation
Website
https://vivtex.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Where Vivtex is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Vivtex business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Licensing Revenue: Vivtex licenses its oral drug-delivery technologies to pharmaceutical partners. Revenue includes upfront payments, research funding, milestone payments, and tiered royalties on future product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Vivtex product offering

Product offering

Core offering

Vivtex develops and licenses an integrated oral biologics delivery platform comprising the GI-ORIS robotic organ interfacing screening system and an AI-driven gastrointestinal formulation platform. The technology enables high-throughput identification of chemical excipients and formulation strategies that allow injectable biologics, particularly peptides, to be delivered orally. Vivtex licenses this proprietary oral drug-delivery technology to pharmaceutical partners such as Novo Nordisk for development of oral therapeutics in metabolic diseases.

Product overview

Vivtex is a biotechnology company offering an integrated oral biologics delivery platform comprising the GI-ORIS robotic screening system and an AI-driven gastrointestinal formulation platform. The core technology enables high-throughput identification of chemical excipients and formulation strategies that allow injectable biologics (particularly peptides) to be delivered orally. Vivtex operates as a platform-and-pipeline company, advancing select oral therapeutic candidates through partnerships with pharmaceutical companies while licensing its delivery technologies. The company focuses on disease areas where oral dosing improves patient quality of life and treatment outcomes, particularly in metabolic disorders requiring frequent long-term dosing.

Differentiator

Problem solved

Functional benefit

Products and services

  • GI-ORIS Platform A robotic organ interfacing technology that enables high-throughput automated screening of the gastrointestinal tract at the organ level, allowing systematic identification of chemicals and formulation combinations that enable drugs to overcome GI absorption barriers. Designed for pharmaceutical and biotech partners.
  • Gastrointestinal Screening and Formulation Platform An AI-driven platform that leverages experimental data from GI-ORIS screening to predict drug-GI interactions and engineer oral formulations for biologics traditionally limited to injection administration. Licensed to pharmaceutical partners for their biologic drug candidates.
  • Oral Peptide Therapeutics Pipeline Vivtex's active pipeline of oral peptide therapeutics targeting metabolic diseases (obesity, diabetes) and other conditions traditionally requiring injectable medications, developed in partnership with pharmaceutical companies.

Quantifiable outcome

  • Technology enables oral bioavailability of injectable biologics, enabling convenient pill/tablet dosing for patients requiring frequent long-term treatment

Companies that use Vivtex

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Vivtex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Vivtex partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Novo NordiskflagshipStrategic or Co-development Partner · 25 February 2026Novo Nordisk partnered with Vivtex in a deal worth up to $2.1 billion to develop next-generation oral biologic medicines for obesity, diabetes, and associated comorbidities. Vivtex licenses its proprietary gastrointestinal screening and formulation platform to enable oral delivery of biologics typically limited to injection. Novo Nordisk leads global development, regulatory activities, manufacturing, and commercialization of resulting products. Vivtex receives upfront payments, research funding, milestone payments, and tiered royalties on future product sales. The collaboration combines Vivtex's oral drug-delivery technologies with Novo Nordisk's peptide and protein therapeutics expertise.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Vivtex competitors and assessment

Company assessment

Direct peers

  • Rani Therapeutics: Develops an oral (pill-based) delivery platform for biologics such as peptides, proteins, and antibodies using a robotic auto-injector capsule. Directly competes with Vivtex in the oral biologic delivery space, targeting chronic disease biologics currently requiring injection.
  • Entera Bio: Develops oral peptide and protein delivery formulations (e.g., oral PTH, oral GLP-1 analogs) using permeability-enhancing excipients. Competes head-to-head with Vivtex on oral bioavailability of injectable peptides, though with a more formulation-led approach rather than robotic screening.
  • Oramed Pharmaceuticals: Pioneer in oral protein delivery (notably oral insulin via POD technology), targeting large injectable biologics for oral reformulation. Most comparable to Vivtex's mission of turning injectable biologics (peptides, hormones) into oral dosage forms.

Broad incumbents

  • Eli Lilly: Global pharma leader developing oral GLP-1 candidates (notably orforglipron) and broader oral peptide programs. A potential acquirer/partner for Vivtex and a comp for the value of validated oral obesity therapeutics to large pharma.
  • Novo Nordisk: Vivtex's flagship partner and the global leader in peptide therapeutics (GLP-1 franchise including Ozempic/Wegovy). Operates its own oral semaglutide and is internalizing oral delivery capability through the Vivtex deal; an essential reference customer and peer for oral biologics.
  • Boehringer Ingelheim: Large pharma with active oral peptide and biologic programs and partnerships focused on improving bioavailability of injectable biologics. Relevant as both a potential licensee/customer and a benchmark for how major pharma pursues oral peptide delivery.

Emerging players

  • BioNxt Solutions: Emerging player developing oral dissolvable thin-film and sublingual delivery of peptides and small molecules. Comparable as a niche company focused on alternative routes of administration versus injectable pharmaceuticals.
  • Lindy Biosciences: Develops formulations for oral and high-concentration biologic delivery, including peptide therapeutics. Comparable niche player focused on novel formulations that enable non-injectable administration of biologics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Vivtex social profiles

Digital presence

Vivtex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vivtex leadership team

Management profile

Number of profiles

Profiles9 records

Vivtex funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vivtex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivtex

What does Vivtex do?

Vivtex develops and licenses an integrated oral biologics delivery platform comprising the GI-ORIS robotic organ interfacing screening system and an AI-driven gastrointestinal formulation platform. The technology enables high-throughput identification of chemical excipients and formulation strategies that allow injectable biologics, particularly peptides, to be delivered orally. Vivtex licenses this proprietary oral drug-delivery technology to pharmaceutical partners such as Novo Nordisk for development of oral therapeutics in metabolic diseases.

Is Vivtex a public or private company?

Vivtex is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Vivtex founded?

Vivtex was founded in 2018. It employs 11 to 50 people.

Where is Vivtex based?

Vivtex is headquartered in Cambridge, United States, in the North America region.

How does Vivtex make money?

One revenue line is on record: licensing Revenue.

Who are Vivtex's main competitors?

Direct peers on record are Rani Therapeutics, Entera Bio and Oramed Pharmaceuticals. Broad incumbents are Eli Lilly, Novo Nordisk and Boehringer Ingelheim. Emerging players are BioNxt Solutions and Lindy Biosciences.

Does Vivtex have an API?

No public API is recorded for Vivtex.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioXconomyNovo & Vivtex team to develop oral meds for obesity and diabetesVivtex will license oral drug-delivery technologies to Novo Nordisk, receiving up to $2.1 billion in upfront, research, and milestone payments plus tiered royalties. The partnership aims to expand oral delivery of biologics, with Novo taking responsibility for development and commercialization.FierceBiotechWith $2B Novo deal in the books, Vivtex isn't 'limited to being just a drug delivery company': CEOVivtex Therapeutics signed a deal in February with Novo Nordisk potentially worth $2.1 billion to help advance next-generation oral metabolic medicines using its gastrointestinal tract mapping technology. The Boston biotech is expanding from its Dorchester incubator into a 10,000-square-foot space in Cambridge while planning to nearly double its headcount to just under 40 employees across Boston and Switzerland. CEO Thomas von Erlach stated the company aims to move beyond being just a drug delivery partner by developing proprietary drug candidates and engineering new drugs designed from the outset for oral delivery.CredenceresearchBiobetters Market Size, Share, Trend, Growth and Forecast 2032The global Biobetters Market was valued at USD 71,522.2 million in 2025 and is projected to reach USD 123,933.49 million by 2032, growing at a compound annual growth rate of 8.17% during the forecast period, driven by rising demand for clinically differentiated biologics across chronic disease pathways. The report provides segment analysis across product types (insulin leading at 44.9%), disease indications (diabetes leading at 49.3%), and distribution channels (hospital pharmacy leading at 52.6%), along with regional breakdowns including North America's 46.70% market share. Recent industry developments include BioNTech's acquisition of Biotheus in February 2025, a BioNTech-Bristol Myers Squibb global partnership for BNT327 in June 2025, and Novo Nordisk's up to USD 2.1 billion partnership with Vivtex Corporation in February 2026.PharmaVoiceNovo regained weight loss footing in the pill arena — but Lilly is comingNovo Nordisk is defending its position in the oral GLP-1 market after gaining ground with its newly approved Wegovy pill, which generated over 600,000 prescriptions in its first two months, while simultaneously facing setbacks in injectable options where its CagriSema failed to outperform Lilly's Zepbound in a head-to-head trial. Eli Lilly is preparing to enter the obesity pill market with orforglipron as early as Q2, having already demonstrated superiority over Novo's Rybelsus in a late-phase study. To strengthen its oral pipeline, Novo announced a partnership worth up to $2.1 billion with biotech startup Vivtex Corporation focused on developing improved oral biologics for obesity, diabetes, and metabolic diseases.openPR.comDrug Delivery Devices Market to Reach US$151.41 Billion by 2033 at 5.9% CAGR; North America Leads with 37% Share - Key Players: Pfizer Inc., Johnson & Johnson, Novartis AGThe global Drug Delivery Devices market reached US$90.40 billion in 2024 and is projected to reach US$151.41 billion by 2033, growing at a 5.9% CAGR, with North America holding 37% market share. Key industry developments include Novo Nordisk's licensing agreement with Vivtex for oral biologic delivery technology (February 2026), Halozyme Therapeutics' acquisition of Elektrofi to expand its high-concentration injectable technology portfolio (October 2025), Johnson & Johnson's launch of a connected medication management platform (October 2025), and Medtronic's new wearable drug delivery device range for chronic disease management (September 2025). The market growth is driven by rising chronic disease prevalence, increasing demand for self-administration and home-based healthcare solutions, and advancements in biologics and personalized medicine.YahooNovo Nordisk A/S (NVO) and Vivtex Corporation Announce a PartnershipNovo Nordisk A/S and Vivtex Corporation announced a partnership on February 25 for the development of next-generation oral biologic medicines targeting obesity, diabetes, and associated comorbidities. Under the agreement, Vivtex will license its oral drug-delivery technologies to Novo Nordisk, with total potential consideration of up to $2.1 billion including upfront payments, research funding, milestone payments, and tiered royalties. Novo Nordisk will leverage Vivtex's gastrointestinal screening and formulation platform alongside its own peptide and protein therapeutics expertise, and will assume responsibility for regulatory activities, global development, manufacturing, and commercialization of any resulting products.Boston.comTwo Boston startups join the race to create the next major weight-loss drugTwo Boston startups, Vivtex and Nimbus Therapeutics, are collaborating with major pharmaceutical companies in their pursuit of developing oral weight-loss medications. Novo Nordisk partnered with Vivtex to develop next-generation drugs, while Eli Lilly partnered with Nimbus Therapeutics, both with potential royalties and project values exceeding $1 billion.GenengnewsNovo Nordisk, Vivtex Ink Up to $2.1B Deal to Develop Oral Biologics for Metabolic ConditionsNovo Nordisk and Vivtex have announced a partnership worth up to $2.1 billion to develop oral biologics for obesity, diabetes, and associated comorbidities, pairing Novo Nordisk's peptide therapeutics expertise with Vivtex's gastrointestinal screening and formulation platform. Vivtex will license its oral drug-delivery technologies to Novo Nordisk, which will assume responsibility for global development, regulatory activities, manufacturing, and commercialization of any resulting products. The deal comes as demand grows for oral treatment options in the metabolic space, with Novo Nordisk having recently launched the world's first oral biologic for obesity.Pharmaceutical TechnologyNovo Nordisk and Vivtex collaborate for oral medicines developmentNovo Nordisk and Vivtex are collaborating on the development of oral medicines, as announced in a news briefing. The article appears to be an industry update without financial details or strategic implications. The focus is on the partnership between the two companies.European Pharmaceutical ReviewNovo Nordisk strikes $2.1bn oral obesity biologic deal with VivtexNovo Nordisk has signed a $2.1 billion licensing deal with biotechnology company Vivtex Corporation to develop next-generation oral biologics for obesity and diabetes, leveraging Vivtex's drug delivery platform that enables high oral bioavailability of biologic drugs traditionally limited to injectable administration. The collaboration builds on Novo Nordisk's launch of the pill form of semaglutide (Wegovy), which received US approval earlier this year as the world's first oral biologic for obesity. CEO Thomas von Erlach stated that the partnership aims to make biologics oral across important metabolic disease areas.